Ffar4 - Model 14386- cKO

• The targeting vector has been generated using C57BL/6J DNA and transfected into TaconicArtemis C57BL/6NTac ES cell line.
• Exon 1 contains the translation initiation codon.
• Exon 1 and approx. 1.5 kb of sequence upstream of exon 1 (promoter region) have been flanked by loxP sites (size of loxP-flanked region: 3.2 kb).
• The positive selection marker (Puromycin resistance - PuroR) has been flanked by FRT sites and inserted into intron 1.
• The conditional KO allele has been generated after Flp-mediated recombination by crossing chimeras to a Flp-Deleter on a C57BL/6 background.
• The conditional KO line has been derived using C57BL/6NTac animals and the Flp-transgene was removed by segregation.
• The constitutive KO allele can be generated by Cre-mediated recombination.
• Deletion of exon 1 and proximal promoter should result in loss of function of the Ffar4 gene, by preventing transcription of the Ffar4 mRNA and by deleting the transmembrane domains 1 to 4.
• The remaining recombination sites will be located in non-conserved regions of the genome.
• Datamining and Design performed 2014.

• US Dollar
• Euro

GEM Collection models exist as cryopreserved materials. Models can typically be recovered and delivered to customers within 14-16 weeks after order receipt. Customers will receive:

• A minimum of four (4) mice mutant for the selected mutation. In rare cases where the cryopreserved material also contains a recombinase gene, this may be reduced to 1-2 mutant mice.
• Validated genotyping protocols
• Animal health report. Mice will meet Taconic's Murine Pathogen Free™ (MPF™) health standard.

Please note that in rare instances (2%) cryorecovery may prove to be difficult, either extending timeline or ultimately successful recovery.

Customers may purchase this model by signing the appropriate Terms of Sale (below) and providing a PO.

• GEM Collection Commercial Terms of Sale
• GEM Collection Academic Terms of Sale

The GEM Collection Commercial and Academic Terms of Sale grant perpetual use rights.